SynAct Pharma AB Sustainability Reports
SynAct Pharma AB is a clinical-stage biotechnology company that conducts research and development on therapeutics targeting the melanocortin system. The company primarily develops medications designed to resolve inflammation and treat autoimmune and inflammatory diseases.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300RRYIEFEQ72N546
FIGI: BBG00CZP0DT9
5 reports from 2021 to 2025